Project Grant R01CA293348
Award Date
6/1/25
Completion Date
4/30/30
Dollars Obligated
$713K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The National Cancer Institute awarded a $1,542,555 Project Grant to Sloan-Kettering Institute For Cancer Research under the Cancer Treatment Research program (CFDA 93.395). The grant will fund research from December 2022 through November 2027 to develop more effective treatments for localized bladder cancer. Specifically, the grantee will conduct genomic analyses of bladder cancer patient cohorts to validate DNA damage response mutations as predictors of sensitivity to bacillus Calmette-Guérin...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $583,973.00 to the Sloan-Kettering Institute for Cancer Research to study the role of EP300 gene mutations in bladder cancer pathogenesis and drug response. The key objectives are to: Investigate how EP300 loss-of-function mutations mediate resistance to the FGFR inhibitor erdafitinib in bladder cancer using patient-derived models. Identify genomic alterations associated with...
This federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $709,554 to Emory University to advance the understanding of how a novel neoadjuvant therapy, combining the antibody pepinemab (which blocks SEMA4D signaling) with immune checkpoint blockade, impacts the immune system in patients with solid tumors, using refractory melanoma as a model. The key objectives are to: 1) gain insight into how blocking SEMA4D impacts...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Icahn School of Medicine at Mount Sinai provides $684,877 to support a multi-scale analysis of the tumor microenvironment in non-muscle invasive bladder cancer (NMIBC). The goal is to elucidate the cellular, genomic, epigenomic, and spatial features that contribute to resistance to Bacillus Calmette-Guérin (BCG) treatment, which is the standard first-line therapy for high-risk NMIBC. The...
This federal Project Grant award of $654,090.00 from the Defense Health Agency is for the "CANCER CELL INTRINSIC REGULATION OF ANTIBODY-DRUG CONJUGATE TARGETS IN BLADDER CANCER" research project at Pennsylvania State University's Milton S. Hershey Medical Center. The research, which runs from September 30, 2024 to September 29, 2026, is funded under the Military Medical Research and Development (CFDA 12.420) program. The project aims to investigate innovative approaches to cancer...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $673,526 to the University of Pittsburgh to conduct research aimed at understanding the mechanisms driving resistance to immune checkpoint blockade (ICB) therapy in melanoma patients with low p16 expression. The key goals are to: Interrogate how p16 loss and dysregulated zinc (Zn) homeostasis, mediated by the Zn transporter SLC39A9, impair cGAS-STING signaling and reduce CXCL10...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $602,881 to Duke University to develop novel immunotherapies using optimized tumor cell-penetrating antibodies. The key objectives are to: Elucidate the mechanisms governing the effectiveness of new IgG antibodies engineered to penetrate cancer cells and neutralize mutated oncogenic drivers like KRAS. This will involve selecting a lead candidate antibody for clinical...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $953,982 to The Trustees of Columbia University in the City of New York to investigate mechanisms of tumor plasticity in human bladder cancer. The key objectives are to: 1) analyze the function of the KMT2D histone methyltransferase in modulating luminal-basal plasticity and drug response in bladder cancer; 2) identify chromatin states...
The National Cancer Institute (NCI), under the Cancer Treatment Research Federal Grant Program (CFDA 93.395), awarded a $400,000 Project Grant to Promilead, LLC in South Carolina to conduct research on enhancing the efficacy of immunotherapy for triple-negative breast cancer (TNBC). The grant aims to evaluate the efficacy of a small-molecule compound, USCYL01, which activates the TFEB protein to favorably modulate tumor-associated macrophages and promote immunogenic cancer cell death, thereby...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $540,288 to the University of Florida to research the role of bacterial-derived small molecules in improving response to immune checkpoint inhibitor (ICI) treatment for non-small cell lung cancer (NSCLC). The key products/services to be delivered include: Defining the functional impact of the bacterial metabolite BAC429 on experimental NSCLC, including its immunostimulatory effects...